Switzerland has become the first European county to approve Pfizer's (PFE) Tofacitinib treatment...


Switzerland has become the first European county to approve Pfizer's (PFE) Tofacitinib treatment for rheumatoid arthritis, which can be used in patients who haven't responded well enough to existing treatments. Tofacitinib has also been authorized in Argentina, Kuwait, the UAE and Russia. The approvals add to those in the U.S. and Japan, where Pfizer plans to launch Tofacitinib with Takeda Pharmaceutical this month. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs